Two PhD positions in Tumor Immunology

Cell surface protein organization determines therapeutic efficacy of cancer antibodiesResearch projectImmunotherapy using antibodies targeting the cell surface has led to important clinicaladvances in patients with cancer. Still, clinical responses of antibody-based therapies arelimited to approximately 20-30% of cancer patients even in conjunction with chemotherapyand/or radiotherapy. One of the major scientific challenges in the oncology field is to increaseour understanding of the mechanisms driving tumor cell escape from therapeutic antibodies.The aim of this project is to decipher how cell surface organization determines the efficacy oftherapeutic cancer antibodies. This will provide molecular and biological insight into theunderlying mechanisms of antibody resistance, and facilitate development of a new class oftherapeutic that modulates tumor cell surface organization.  

We are looking for
Two creative and motivated researchers with a master degree in biomedical sciences/
biology/biochemistry or equivalent. PhD#1 will characterize the organization of therapeutic
antibodies on melanoma/myeloma cells and decipher how that affects recognition by dendritic
cells (immunology/cell biology background). PhD#2 will focus on modulating the organization
of checkpoint inhibitors (PD-L1) in tumor membranes and in generating new antibody-based
therapeutics (cell biology/chemical background). Some experience with immunological, cell
biological and/or molecular biology techniques is a must. For both projects, a permit to work
with animals (or willing to obtain this) is an advantage.

job type
start 18-03-2021
end 05-04-2021
organisation Radboud UMC
department The department of tumor immunology
location Radboud Institute for Molecular Life Sciences

Information: Prof. dr. A.B. van Spriel, Dr. L. Querol-Cano



Application deadline: April 5th, 2021

organization profile

We are
The department of tumor immunology aims at a better understanding of our immune system
using molecular-, cell biological- and immunological- techniques and is centered around
dendritic cells and lymphocytes which are key cells in anti-tumor immunity. Our multidisciplinary
Department combines fundamental with translational research, including different
clinical trials of dendritic cell immunotherapy in cancer patients. We are embedded within the
Radboud Institute for Molecular Life Sciences (RIMLS), a leading European research school
that provides an outstanding, multi-cultural and thriving research setting within the Radboud
University Medical Center. RIMLS innovations are advanced through technology platforms
such as genomics, proteomics, and advanced imaging.

print this page
Webdesign © 2008 Strik Design